Aurobindo Pharma Limited (BOM:524804)

Aurobindo Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	33,935	43,963	41,625	53,735	27,637
Short-Term Investments	29,329	18,364	4,038	2,580	759.1
Trading Asset Securities	0.1	0.1	0.1	0.2	0.2
Cash & Short-Term Investments	63,264	62,327	45,663	56,315	28,396
Cash Growth	1.50%	36.49%	-18.92%	98.32%	45.26%
Accounts Receivable	48,167	44,664	40,123	35,033	43,152
Other Receivables	5,150	5,356	3,619	4,979	4,894
Receivables	53,446	50,144	43,869	40,155	48,182
Inventory	98,082	85,112	75,539	90,266	76,999
Other Current Assets	27,265	17,874	16,157	11,500	10,548
Total Current Assets	242,056	215,457	181,227	198,235	164,125
Property, Plant & Equipment	142,849	124,918	106,660	93,155	81,166
Long-Term Investments	3,216	3,917	6,183	4,312	5,547
Goodwill	5,952	5,961	4,754	4,289	9,159
Other Intangible Assets	32,874	31,279	29,587	25,546	23,420
Long-Term Deferred Tax Assets	12,126	6,775	2,886	4,527	1,632
Long-Term Deferred Charges	1,941	1,980	1,792	1,361	78.2
Other Long-Term Assets	9,643	8,558	6,065	7,042	4,091
Total Assets	450,715	398,900	339,217	338,540	289,277
Accounts Payable	44,542	38,713	27,031	27,947	25,761
Accrued Expenses	17,924	16,378	12,165	14,918	19,607
Short-Term Debt	41,685	42,304	21,178	48,038	54,223
Current Portion of Long-Term Debt	117.8	121.3	57.3	-	1,397
Current Portion of Leases	798.8	1,032	1,599	1,006	1,110
Current Income Taxes Payable	2,490	2,116	580.3	2,104	950.8
Current Unearned Revenue	2,703	3,889	5,679	110.3	10.1
Other Current Liabilities	11,731	10,385	13,272	12,528	10,788
Total Current Liabilities	121,991	114,938	81,560	106,651	113,846
Long-Term Debt	21,349	6,190	2,492	1,685	-
Long-Term Leases	2,525	3,215	3,186	2,662	2,644
Long-Term Unearned Revenue	363.5	-	-	-	-
Long-Term Deferred Tax Liabilities	3,566	3,896	4,110	5,746	2,917
Other Long-Term Liabilities	1,665	1,491	1,524	2,052	900
Total Liabilities	152,207	130,381	93,477	119,250	121,029
Common Stock	585.9	585.9	585.9	585.9	585.9
Additional Paid-In Capital	4,179	4,179	4,179	4,179	4,179
Retained Earnings	276,146	247,236	233,322	209,499	158,556
Comprehensive Income & Other	17,517	16,398	7,674	5,035	4,926
Total Common Equity	298,428	268,399	245,760	219,299	168,247
Minority Interest	80	120	-19.3	-8.8	1.4
Shareholders' Equity	298,508	268,519	245,741	219,290	168,248
Total Liabilities & Equity	450,715	398,900	339,217	338,540	289,277
Total Debt	66,476	52,862	28,513	53,391	59,374
Net Cash (Debt)	-3,213	9,465	17,150	2,924	-30,977
Net Cash Growth	-	-44.81%	486.55%	-	-
Net Cash Per Share	-5.48	16.15	29.27	4.99	-52.87
Filing Date Shares Outstanding	585.94	585.94	585.94	585.94	585.94
Total Common Shares Outstanding	585.94	585.94	585.94	585.94	585.94
Working Capital	120,065	100,519	99,667	91,585	50,279
Book Value Per Share	509.32	458.07	419.43	374.27	287.14
Tangible Book Value	259,602	231,159	211,419	189,464	135,667
Tangible Book Value Per Share	443.05	394.51	360.82	323.35	231.54
Land	8,686	8,303	6,518	2,860	2,534
Buildings	46,978	32,564	25,645	24,177	22,756
Machinery	119,040	88,308	76,809	67,543	59,187
Construction In Progress	27,394	44,964	29,376	24,289	16,218

Source: S&P Global Market Intelligence. Standard template. Financial Sources.